Boston Oncology Arabia is a fully integrated pharmaceutical company operating within Saudi Arabia — enabling coordinated execution from regulatory strategy through clinical use.
Launched in 2018, Boston Oncology Arabia is the first full implementation of our model within a national healthcare system — enabling coordinated execution across regulatory pathways, manufacturing, and hospital access.
This structure translates directly into rapid adoption and sustained clinical use across the healthcare system — converting regulatory success into real-world patient impact.
hospitals served*
purchase orders annually*
units manufacturing capacity*
Immunology therapies achieving broad adoption across government hospital systems
Step-change increases in utilization of complex biologic therapies following localized market entry²
Established therapies becoming first-line standards across national treatment networks³
Source: Boston Oncology Arabia internal operating and manufacturing records. *Hospital coverage represents 120 active, unique hospital and customer delivery locations. Purchase-order volume represents 1,200 unique purchase orders reported for the 2026 operating period. Manufacturing capacity represents more than 30 million units annually across two installed and validated production lines supporting seven formats. ¹Adalimumab: 100% market share across [defined Saudi government hospital universe], [measurement period]. ²Tocilizumab: 235% growth in utilization following BOA’s localized market entry, measured against [baseline] over [measurement period]. ³Enoxaparin: first-line adoption across [defined Saudi government hospital universe], as of [date].
Boston Oncology Arabia operates SFDA cGMP-certified manufacturing facilities designed for the production of complex and high-value medicines, including biologics, specialty injectables, and complex sterile formulations.
Facilities are built to support:
Localized manufacturing enables reliable supply, reduces dependency on external sources, and supports sustained access across healthcare systems.
A fully operational manufacturing environment built for complex, high-value therapies
Commercial execution is embedded within Saudi Arabia’s healthcare system — carefully aligned with national procurement structures, hospital networks, and treatment pathways.
Unlike traditional expansion models that rely on layered intermediaries, Boston Oncology operates directly across purchasing mechanisms, institutional stakeholders, and clinical pathways — removing fragmentation and ensuring alignment from approval through sustained clinical use.
Through local manufacturing, technology transfer, and the localization of complex medicines, Boston Oncology Arabia is building lasting pharmaceutical capability within the Kingdom.
This directly supports Saudi Vision 2030’s healthcare and industrial-development priorities—advancing specialized talent, strengthening medicine security, reducing dependence on external supply, and supporting reliable patient access.
Saudi Arabia is Boston Oncology Arabia’s operating center and the foundation of its emerging regional footprint.
From this base, BOA supports expansion across GCC and MENA healthcare markets—extending regulatory coordination, manufacturing capability, and in-market execution into adjacent systems.
From its base in Saudi Arabia, Boston Oncology Arabia supports expansion across GCC and MENA healthcare markets — extending localized manufacturing, regulatory alignment, and in-market execution into adjacent systems.
